Video yรผkleniyor...

Video Yรผklenemedi

Ana Sayfaya Dรถn

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

BiotechTV's profile picture

BiotechTV

11,925 subscribers

17,244 gรถrรผntรผleme โ€ข 2 ay รถnce โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gรถnderinin yorumlarฤฑ burada gรถrรผnecek

Benzer Videolar

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:
6:11

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:

BiotechTV

11,722 gรถrรผntรผleme โ€ข 4 ay รถnce

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!
0:48

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

BiotechTV

20,856 gรถrรผntรผleme โ€ข 2 ay รถnce

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:
3:49

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:

BiotechTV

25,829 gรถrรผntรผleme โ€ข 8 ay รถnce

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: John Maraganore ๐Ÿ‡บ๐Ÿ‡ธ๐Ÿ‡ฌ๐Ÿ‡ท๐Ÿ‡บ๐Ÿ‡ฆ has been a champion of innovation throughout his career. He and Matt Gline discuss the road to success at Alnylam Pharmaceuticals, today's environment, and keeping the U.S. on top. Watch the episode:
0:33

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: John Maraganore ๐Ÿ‡บ๐Ÿ‡ธ๐Ÿ‡ฌ๐Ÿ‡ท๐Ÿ‡บ๐Ÿ‡ฆ has been a champion of innovation throughout his career. He and Matt Gline discuss the road to success at Alnylam Pharmaceuticals, today's environment, and keeping the U.S. on top. Watch the episode:

BiotechTV

20,288 gรถrรผntรผleme โ€ข 5 ay รถnce

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Matt Gline speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector. Full video:
7:13

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Matt Gline speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector. Full video:

BiotechTV

20,811 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:
1:05

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:

BiotechTV

16,344 gรถrรผntรผleme โ€ข 8 ay รถnce

๐๐ž๐ฐ ๐’๐ก๐จ๐ฐ ๐€๐ง๐ง๐จ๐ฎ๐ง๐œ๐ž๐ฆ๐ž๐ง๐ญ: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:
2:56

๐๐ž๐ฐ ๐’๐ก๐จ๐ฐ ๐€๐ง๐ง๐จ๐ฎ๐ง๐œ๐ž๐ฆ๐ž๐ง๐ญ: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:

BiotechTV

37,153 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions. $XBI $XENE $MDGL $ALKS Full video:
4:30

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions. $XBI $XENE $MDGL $ALKS Full video:

BiotechTV

13,777 gรถrรผntรผleme โ€ข 10 ay รถnce

๐๐ข๐จ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐•๐จ๐ข๐‚๐ž๐ฌ: An early investor in recent mega successes such as Revolution Medicines, Peloton, Blueprint Medicines, and Parabilis, Thilo Schroeder describes his investment philosophy and focus on precision oncology. Full video:
8:50

๐๐ข๐จ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐•๐จ๐ข๐‚๐ž๐ฌ: An early investor in recent mega successes such as Revolution Medicines, Peloton, Blueprint Medicines, and Parabilis, Thilo Schroeder describes his investment philosophy and focus on precision oncology. Full video:

BiotechTV

13,827 gรถrรผntรผleme โ€ข 3 ay รถnce

Founder + CEO of biotech firm Enveda shares why the most successful drugs in history trace back to living cells, and how his team built the world's first sequencer to decode them. Watch the full conversation with Viswa Colluru:
0:49

Founder + CEO of biotech firm Enveda shares why the most successful drugs in history trace back to living cells, and how his team built the world's first sequencer to decode them. Watch the full conversation with Viswa Colluru:

NYSE ๐Ÿ›

988,457 gรถrรผntรผleme โ€ข 23 gรผn รถnce

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!
1:37

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!

BiotechTV

12,276 gรถrรผntรผleme โ€ข 8 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:
3:01

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,305 gรถrรผntรผleme โ€ข 2 ay รถnce

๐”.๐’. ๐’๐œ๐ข๐ž๐ง๐œ๐ž ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ: Alexis Borisy shares his take on one of today's biggest debates in biotech, the impact of China on the U.S. biotech sector.
4:15

๐”.๐’. ๐’๐œ๐ข๐ž๐ง๐œ๐ž ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ: Alexis Borisy shares his take on one of today's biggest debates in biotech, the impact of China on the U.S. biotech sector.

BiotechTV

12,238 gรถrรผntรผleme โ€ข 1 ay รถnce

In this episode of #TheSecretaryKennedyPodcast, Mike Tyson opens up about his childhood, growing up on ultra-processed food, and how mentorship and discipline changed his life. Watch the full episode now:
0:53

In this episode of #TheSecretaryKennedyPodcast, Mike Tyson opens up about his childhood, growing up on ultra-processed food, and how mentorship and discipline changed his life. Watch the full episode now:

Secretary Kennedy

41,352 gรถrรผntรผleme โ€ข 4 ay รถnce

๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ญ ๐“๐ก๐ฎ๐ซ๐ฌ๐๐š๐ฒ๐ฌ: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:
3:27

๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ญ ๐“๐ก๐ฎ๐ซ๐ฌ๐๐š๐ฒ๐ฌ: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:

BiotechTV

29,397 gรถrรผntรผleme โ€ข 7 ay รถnce